Anyone supposing that global medtech deals have hit the buffers would have been otherwise enlightened at the LSX World Congress, in London, in February 2019. True, Brexit might see confidence take a short-term dip, health systems are fighting for budget and using their reimbursement spends ever-more-carefully, and the forthcoming Medical Device Regulation is painting a somewhat forbidding picture for would-be start-ups up and device innovators in the EU.
But a high-level panel debate on the current climate for adding growth externally put to bed the notion that M&A...
